GeneHealth - Your precision medicine

Amyotrophic Lateral Sclerosis Type 11

Disease Details

Family Health Simplified

Buy Membership

Description: Amyotrophic lateral sclerosis type 11 (ALS11) is a rare, inherited form of ALS characterized by progressive degeneration of motor neurons, leading to muscle weakness and atrophy.
Type: Amyotrophic lateral sclerosis type 11 (ALS11) is an autosomal dominant disorder.
Signs And Symptoms: Amyotrophic lateral sclerosis type 11 (ALS11) shares many features with other forms of ALS. Typically, signs and symptoms include:

- Muscle weakness and atrophy
- Twitching (fasciculations) and cramping of muscles
- Difficulty in speaking (dysarthria)
- Trouble swallowing (dysphagia)
- Respiratory complications
- Stiffness and abnormal muscle tightness (spasticity)

Progression varies, but ALS generally leads to increasing disability and can impact the ability to move, speak, eat, and breathe independently.
Prognosis: Amyotrophic lateral sclerosis type 11 (ALS11), a subtype of amyotrophic lateral sclerosis (ALS), is a progressive neurodegenerative disorder primarily affecting motor neurons. The prognosis for ALS11, like other forms of ALS, is generally poor. The disease leads to increasing muscle weakness and atrophy, eventually impacting respiratory muscles, which can result in respiratory failure. Survival time after diagnosis typically ranges from 2 to 5 years, though some patients may live longer with appropriate supportive care. There is no cure for ALS11, and treatment focuses on symptom management and improving quality of life.
Onset: Amyotrophic lateral sclerosis type 11 (ALS11) typically has an onset in adulthood. The specific age range can vary, but symptoms generally begin in midlife.
Prevalence: The prevalence of amyotrophic lateral sclerosis type 11 (ALS11) is not well-documented due to its rarity. ALS11 is a specific genetic subtype of amyotrophic lateral sclerosis (ALS), which itself has an estimated prevalence of approximately 2 to 5 cases per 100,000 people globally. However, ALS11, like other genetic subtypes, constitutes a very small fraction of overall ALS cases.
Epidemiology: Amyotrophic lateral sclerosis type 11 (ALS11) is a rare subtype of amyotrophic lateral sclerosis, a progressive neurodegenerative disorder affecting motor neurons. Due to its rarity, specific epidemiological data for ALS11 are not well-established. Generally, ALS has an incidence rate of 1-2 cases per 100,000 people per year globally, but precise statistics for ALS11 are limited due to its genetic specificity and the overall rarity of genetic subtypes. Further studies are needed to accurately determine the epidemiology of ALS11.
Intractability: Yes, Amyotrophic Lateral Sclerosis Type 11 (ALS11) is considered intractable. ALS11 is a genetic form of ALS characterized by progressive degeneration of motor neurons, leading to muscle weakness, atrophy, and ultimately respiratory failure. There is currently no cure for ALS11, and treatment focuses on managing symptoms and improving quality of life.
Disease Severity: Disease Severity: Amyotrophic lateral sclerosis type 11 (ALS11) is typically characterized by progressive muscle weakness and atrophy, with symptoms often beginning in the limbs or bulbar muscles. Like other forms of ALS, it is generally severe and leads to significant disability over time.

Nan: Not applicable.
Healthcare Professionals: Disease Ontology ID - DOID:0060202
Pathophysiology: Amyotrophic lateral sclerosis type 11 (ALS11) is a subtype of amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disorder. The hallmark of ALS11, like other forms of ALS, involves the degeneration of both upper and lower motor neurons. This leads to muscle weakness, atrophy, and eventually paralysis. Specific to ALS11, pathogenic mutations are found in the Fused in Sarcoma (FUS) gene.

### Pathophysiology of ALS11:
1. **FUS Gene Mutation**: Mutations in the FUS gene result in abnormal RNA binding protein function. The FUS protein usually plays a role in RNA metabolism including RNA splicing, transport, and translation.

2. **Protein Aggregation**: Mutant FUS protein tends to mislocalize to the cytoplasm and form insoluble aggregates, disrupting normal cellular processes.

3. **Impaired RNA Metabolism**: Disrupted function of FUS affects RNA processing mechanisms, leading to widespread cellular dysfunction.

4. **Mitochondrial Dysfunction**: There may be increased mitochondrial dysfunction and oxidative stress in neurons, contributing to cell death.

5. **Neuronal Degeneration**: Progressive loss of motor neurons due to the combined effects of these pathological processes leads to the clinical manifestations of ALS.

Unfortunately, more specific detailed nan pathophysiology of ALS11 is not well-understood. The primary focus remains on understanding how FUS mutations lead to motor neuron degeneration.
Carrier Status: Amyotrophic lateral sclerosis type 11 (ALS11) is caused by mutations in the FIG4 gene. Carrier status pertains to individuals who have one mutated copy of a gene and one normal copy. In the case of ALS11, which follows an autosomal recessive inheritance pattern, carriers typically do not show symptoms because they have one functioning copy of the gene. Symptoms usually only manifest when an individual inherits two mutated copies, one from each parent. Carrier status can be determined through genetic testing.
Mechanism: Amyotrophic lateral sclerosis type 11 (ALS11) is a subtype of amyotrophic lateral sclerosis (ALS), which is a neurodegenerative disorder characterized by the progressive loss of motor neurons. The mechanism and molecular mechanisms for ALS11 can be summarized as follows:

### Mechanism:
ALS11 typically involves the degeneration of both upper and lower motor neurons. The exact cellular mechanisms are still under investigation, but it is known that the degeneration leads to muscle weakness, atrophy, and eventually paralysis.

### Molecular Mechanisms:
1. **Genetic Mutation**: ALS11 is often linked to mutations in the FIG4 gene, which encodes a protein involved in phosphoinositide metabolism. These mutations can lead to dysfunctional lipid signaling pathways.

2. **Impaired Vesicular Trafficking**: FIG4 plays a crucial role in endosomal trafficking and autophagy. Mutations in FIG4 can impair these processes, leading to the accumulation of toxic proteins and cellular components in motor neurons.

3. **Abnormal Lipid Metabolism**: FIG4 mutations affect the regulation of phosphoinositides, which are critical for membrane dynamics and signaling. This disruption can interfere with cell signaling pathways crucial for neuron survival.

4. **Neuroinflammation**: Aberrant function of FIG4 can trigger inflammatory responses in the central nervous system, contributing to motor neuron damage.

5. **Mitochondrial Dysfunction**: FIG4 mutations may also affect mitochondrial function, leading to oxidative stress and energy deficits in neurons.

Understanding these molecular mechanisms is critical for developing targeted therapies for ALS11. Research is ongoing to elucidate the pathways involved and to find potential interventions that could mitigate the progression of the disease.
Treatment: Amyotrophic lateral sclerosis type 11 (ALS11) is a specific subtype of ALS, which is a neurodegenerative disorder characterized by the progressive loss of motor neurons.

Treatment for ALS11, like other forms of ALS, primarily focuses on managing symptoms and improving quality of life since there is no cure. The treatment plan typically includes:

1. **Medications:**
- **Riluzole**: May slow disease progression.
- **Edaravone**: Can help reduce the decline in daily functioning.

2. **Physical Therapy:**
- Helps maintain muscle strength and mobility, reducing spasticity and pain.

3. **Occupational Therapy:**
- Assists in improving the ability to perform daily activities by adapting new strategies and tools.

4. **Speech Therapy:**
- Helps manage speech and communication difficulties as the disease progresses.

5. **Respiratory Support:**
- Non-invasive ventilation (such as BiPAP) can be used when respiratory muscles weaken.
- In advanced stages, mechanical ventilation might be considered.

6. **Nutritional Support:**
- A dietitian can provide guidance on maintaining proper nutrition and may suggest feeding tubes if swallowing becomes difficult.

7. **Multidisciplinary Care:**
- A team approach involving neurologists, pulmonologists, physiotherapists, and other specialists can provide comprehensive care.

Research is ongoing to find more effective treatments for ALS, including gene therapy and stem cell therapy, but these are still in experimental stages.
Compassionate Use Treatment: Amyotrophic lateral sclerosis type 11 (ALS11) is a specific form of ALS associated with a mutation in the FIG4 gene. For ALS and its subtypes like ALS11, treatments under compassionate use or experimental and off-label categories vary. Here are some potential options:

1. **Compassionate Use Treatments**:
- **NurOwn (MSC-NTF cells)**: This stem cell therapy is provided through compassionate use by BrainStorm Cell Therapeutics in certain cases.
- **Tofersen**: An antisense oligonucleotide targeting SOD1 mutations, offered on a compassionate basis in some regions for specific genetic mutations related to ALS.

2. **Off-Label Treatments**:
- **Riluzole**: Although officially approved for ALS, it is sometimes used off-label at varied dosages or in combination with other treatments.
- **Nuedexta (dextromethorphan/quinidine)**: Primarily approved for pseudobulbar affect, some clinicians use it off-label for ALS-related symptoms.

3. **Experimental Treatments**:
- **Gene Therapy**: Investigational therapies like antisense oligonucleotides (ASOs) are being studied for specific genetic variants of ALS.
- **Stem Cell Therapies**: Research on stem cells, including mesenchymal stem cells (MSCs) and induced pluripotent stem cells (iPSCs), is ongoing.
- **Edaravone**: Although approved, its exact mechanism and full potential in various ALS types, including ALS11, are still under investigation.
- **AMX0035**: A combination therapy of sodium phenylbutyrate and taurursodiol showing promise in clinical trials.

It's important to consult with healthcare providers and specialists for personalized information and access to the latest experimental treatments.
Lifestyle Recommendations: For amyotrophic lateral sclerosis type 11 (ALS11), lifestyle recommendations focus on improving quality of life and managing symptoms:

1. **Nutrition:**
- Maintain a balanced diet rich in nutrients.
- Consider high-calorie, nutrient-dense foods if weight loss is a concern.
- Consult a dietitian for tailored nutritional advice.

2. **Exercise:**
- Engage in low-impact exercises like swimming, walking, or stationary biking to maintain muscle strength and cardiovascular health.
- Stretching and range-of-motion exercises can help reduce stiffness and maintain flexibility.
- Work with a physical therapist to design a safe and effective exercise regimen.

3. **Assistive Devices:**
- Use braces, walkers, or wheelchairs as needed to maintain mobility and reduce the risk of falls.
- Adaptive devices like speech-generating devices or special utensils can help maintain independence in daily activities.

4. **Respiratory Care:**
- Regular monitoring of lung function.
- Breathing exercises and possibly the use of non-invasive ventilatory support (e.g., BiPAP) may be recommended.

5. **Psychological Support:**
- Engage in regular mental health care, such as counseling or support groups.
- Maintain social connections to alleviate feelings of isolation and depression.

6. **Regular Medical Follow-up:**
- Frequent check-ups with neurologists and other specialists to monitor disease progression and adjust treatments as necessary.

Early intervention and proactive management of symptoms can significantly improve the quality of life for individuals with ALS11.
Medication: Amyotrophic lateral sclerosis (ALS) type 11, like other forms of ALS, does not have a cure, but treatment options aim to manage symptoms and improve quality of life. Medications typically used include:

1. **Riluzole**: Slows the progression of the disease.
2. **Edaravone**: Helps reduce the decline in daily functioning.
3. **Baclofen or Tizanidine**: May be prescribed to help manage spasticity.
4. **Modafinil**: Sometimes used to treat fatigue.
5. **Antidepressants**: For emotional and psychological support.

Other interventions such as physical therapy, respiratory care, and nutritional support are essential. You should consult a healthcare professional for a treatment plan that is tailored to individual needs.
Repurposable Drugs: There are currently no specific repurposable drugs commonly associated with amyotrophic lateral sclerosis type 11 (ALS11). Research is ongoing to find potential therapies. Maintaining close communication with healthcare professionals for the latest treatment options and clinical trials is recommended.
Metabolites: There is currently no specific information available that directly links unique metabolites to amyotrophic lateral sclerosis type 11 (ALS11). ALS11 is a form of ALS caused by mutations in the FIG4 gene. As ALS is a highly heterogeneous disease, research is ongoing to identify metabolic biomarkers that may be associated with various subtypes of ALS, including ALS11. General metabolomic studies on ALS have identified changes in amino acids, lipids, and energy metabolism, but these findings are not exclusive to any specific subtype.
Nutraceuticals: Currently, there is no well-established evidence supporting the effectiveness of nutraceuticals in treating amyotrophic lateral sclerosis type 11 (ALS11). ALS11 is a genetic subtype of ALS, caused by mutations in specific genes, and it leads to progressive degeneration of motor neurons. Treatment primarily focuses on symptom management and slowing disease progression with FDA-approved drugs like Riluzole and Edaravone. Always consult a healthcare professional before considering any supplements or alternative treatments.
Peptides: Amyotrophic lateral sclerosis type 11 (ALS11) is a subtype of ALS associated with mutations in the FIG4 gene. Peptides are short chains of amino acids and can be involved in various biological processes, including signaling pathways that may be disrupted in ALS. Currently, specific peptide-based treatments for ALS11 are not well established. Research on targeted therapies and their potential effects on FIG4-related pathways is ongoing.